Comparison of the Effect of Honey and Diphenhydramine on Children's Nocturnal Cough and Sleep Quality

Comparison of the Effect of Two Kinds of Iranian Honey and Diphenhydramine on Nocturnal Cough and Sleep Quality in Coughing Children and Their Parents

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014090819037N1

Enrollment

150

Registered

2014-10-10

Start date

2013-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nocturnal cough due to acute upper respiratory tract infection. upper respiratory infection (acute)

Interventions

Intervention 1: Control group: Oral solution of Diphenhydramine HCl from Ramopharmin drug manufacturing company, Tehran, Iran, registered No. 1228056772 (Patients in this group receive their treatment

Treatment - Drugs

Control group: Oral solution of Diphenhydramine HCl from Ramopharmin drug manufacturing company, Tehran, Iran, registered No. 1228056772 (Patients in this group receive their treatments within 30 mi

First intervention group Kimia Honey from Kimia company, Ardabil, Iran, registered No. 4916 (Patients in this group receive their treatments within 30 minutes before going to sleep at two subsequent

Second intervention group: ShahdeGolha Honey from ShahdeGolha company, Khorasan-e Razavi, Iran, registered No. 73294 (Patients in this group receive their treatments within 30 minutes before going t

Eligibility

Sex/Gender

All

Age

2 Years to 12 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Presence of cough with or without rhinorrhea for at most 7 days; Congestion; fever (oral temperature less than 39°); pharyngitis; malaise; headache Exclusion criteria: Presence of asthma; pneumonia; laryngotracheobronchitis; sinusitis; allergic rhinitis; baseline disease; frequent hospitalization; recent consuming of diphenhydramine

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of children's nocturnal cough. Timepoint: up to 48 hours of treatment. Method of measurement: Same questionnaire before and after the treatment.;Frequency of children's nocturnal cough. Timepoint: up to 48 hours of treatment. Method of measurement: Same questionnaire before and after the treatment.;The bothersome nature of children's nocturnal cough. Timepoint: up to 48 hours of treatment. Method of measurement: Same questionnaire before and after the treatment.	—

Measure

Time frame

Severity of children's nocturnal cough. Timepoint: up to 48 hours of treatment. Method of measurement: Same questionnaire before and after the treatment.;Frequency of children's nocturnal cough. Timepoint: up to 48 hours of treatment. Method of measurement: Same questionnaire before and after the treatment.;The bothersome nature of children's nocturnal cough. Timepoint: up to 48 hours of treatment. Method of measurement: Same questionnaire before and after the treatment.

—

Secondary

Measure	Time frame
The quality of nocturnal sleep in patients' parents. Timepoint: up to 48 hours of treatment. Method of measurement: Same questionnaire before and after the treatment.;The quality of nocturnal sleep in patients. Timepoint: up to 48 hours of treatment. Method of measurement: Same questionnaire before and after the treatment.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026